October 28, 2016 12:06 PM ET

Healthcare Equipment and Supplies

Company Overview of CardioFocus, Inc.

Company Overview

CardioFocus, Inc. develops an endoscopic ablation system for the treatment of cardiac disorders (atrial fibrillation) in the United States. CardioFocus, Inc. was formerly known as Rare Earth Medical, Inc. and changed its name to CardioFocus, Inc. in June 1999. The company was incorporated in 1990 and is based in Marlborough, Massachusetts.

500 Nickerson Road

Suite 500-200

Marlborough, MA 01752

United States

Founded in 1990





Key Executives for CardioFocus, Inc.

Chief Executive Officer, President and Director
Executive Chairman
Age: 58
Founder and Chief Technology Officer
Chief Financial Officer and Treasurer
Vice President of Operations
Compensation as of Fiscal Year 2016.

CardioFocus, Inc. Key Developments

CardioFocus, Inc. Announces Management Appointments

CardioFocus, Inc. announced the appointment of Omari Bouknight as Chief Commercial Officer and Jeff Rynbrandt as Vice President of U.S. Sales. Together they will lead the commercialization of the HeartLight® Endoscopic Ablation System. In the newly created role of Chief Commercial Officer, Mr. Bouknight will lead and integrate the U.S. and EU commercial teams and oversee the company's launch efforts. In the newly created role of Vice President of U.S. Sales, Mr. Rynbrandt will be responsible for building and leading a domestic field sales force. Prior to joining CardioFocus, Mr. Bouknight held the role of Vice President of Sales and Marketing for Cardiac Dimensions. Before joining CardioFocus, Mr. Rynbrandt built and led cohesive sales teams to success within a variety of electrophysiology markets.

CardioFocus, Inc. Receives FDA Approval for HeartLight Endoscopic Ablation System for Treatment of Atrial Fibrillation

CardioFocus, Inc. announced that it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for its HeartLight® Endoscopic Ablation System for the treatment of patients with paroxysmal atrial fibrillation (AF). The approved PMA submission contained comprehensive safety and effectiveness data from the Company's multi-center HeartLight U.S. Pivotal Clinical Study, a randomized, controlled study in which a total of 353 participants were randomized at 19 arrhythmia centers across the United States. Results from the pivotal trial, announced at Heart Rhythm 2015, showed that when performing a single ablation procedure using the HeartLight System.

CardioFocus, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 01:20 PM

CardioFocus, Inc. Presents at Canaccord Genuity 2015 Medical Technology & Diagnostics Forum, Nov-19-2015 01:20 PM. Venue: Westin Grand Central, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Private Placement
May 11, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CardioFocus, Inc., please visit www.cardiofocus.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.